This company listing is no longer active
bluebird bio Management
Management criteria checks 3/4
bluebird bio's CEO is Andrew Obenshain, appointed in Nov 2021, has a tenure of 3.5 years. total yearly compensation is $1.83M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 0.092% of the company’s shares, worth MX$866.62K. The average tenure of the management team and the board of directors is 3.3 years and 14.2 years respectively.
Key information
Andrew Obenshain
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 39.94% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.09% |
| Management average tenure | 3.3yrs |
| Board average tenure | 14.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$200m |
| Dec 31 2024 | US$2m | US$729k | -US$241m |
| Sep 30 2024 | n/a | n/a | -US$293m |
| Jun 30 2024 | n/a | n/a | -US$319m |
| Mar 31 2024 | n/a | n/a | -US$301m |
| Dec 31 2023 | US$3m | US$682k | -US$212m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$89m |
| Dec 31 2022 | US$2m | US$643k | -US$230m |
| Sep 30 2022 | n/a | n/a | -US$431m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$563m |
| Dec 31 2021 | US$9m | US$486k | -US$563m |
Compensation vs Market: Andrew's total compensation ($USD1.83M) is above average for companies of similar size in the MX market ($USD186.11K).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
CEO
Andrew Obenshain (49 yo)
Mr. Andrew Obenshain has been the President, Chief Executive Officer and Director of bluebird bio, Inc. since November 2021. He served as President of Severe Genetic Diseases since October 2020 until Novem...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$1.83m | 0.092% MX$ 866.6k | |
| Chief Commercial & Operating Officer | 2.7yrs | US$850.72k | 0.035% MX$ 327.7k | |
| Chief Legal & Business Officer and Secretary | 2.3yrs | US$897.29k | 0.012% MX$ 109.7k | |
| CFO & Principal Accounting Officer | less than a year | no data | no data | |
| Chief People Officer | 3.3yrs | no data | no data | |
| Chief Medical Officer | 4.2yrs | US$1.34m | 0.028% MX$ 264.6k | |
| Senior Vice President of Technical Operations | 4.3yrs | no data | no data |
Experienced Management: BLUE *'s management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$1.83m | 0.092% MX$ 866.6k | |
| Member of Scientific Advisory Board | 14.2yrs | no data | no data | |
| Co-Chair of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 14.2yrs | no data | no data | |
| Independent Chairman | 10.8yrs | US$132.40k | 0.013% MX$ 120.2k | |
| Member of Scientific Advisory Board | 9.8yrs | US$1.57m | no data | |
| Member of Scientific Advisory Board | 14.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 14.2yrs | no data | no data | |
| Independent Director | 7.9yrs | US$92.40k | 0.014% MX$ 127.0k | |
| Director | 15.2yrs | US$27.40k | 0.23% MX$ 2.2m | |
| Member of Scientific Advisory Board | 14.2yrs | no data | no data | |
| Independent Director | 3.5yrs | US$99.90k | 0.011% MX$ 106.8k |
Experienced Board: BLUE *'s board of directors are seasoned and experienced ( 14.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 15:33 |
| End of Day Share Price | 2025/04/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
bluebird bio, Inc. is covered by 24 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Matthew Luchini | BMO Capital Markets Equity Research |
| Dane Leone | BTIG |